In 374 adults with recurrent/metastatic head and neck squamous cell carcinoma progressing after platinum and anti-PD-(L)1 therapy, lenvatinib-pembrolizumab did not improve OS vs standard of care (median 8.4 vs 11.3 months; HR 1.48) and had more discontinuations.
RCTn = 374
Kim et al. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial